Canaccord raised the firm’s price target on Arcellx to $121 from $85 and keeps a Buy rating on the shares. The firm said their target increase is based on higher anito-cel revenues and given the existing CARVYKTI sales ramp, they raise their revenue projections for anito-cel in the US to $531M from $419M in 2030.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACLX: